Tackling fibrosis: Galecto raises $64m in equity financing

2048px-Non-alcoholic_fatty_liver_disease1
Galecto is focused on developing innovative drugs for fibrosis-associated diseases, including IPF and NASH. Credit: Nephron via Wikimedia.